专题：2026亚布力论坛年会
2026亚布力论坛年会于3月17日-19日在黑龙江亚布力举办。中国生物制药有限公司首席执行长，正大天晴、北京泰德董事长谢承润表示，数据显示，我国新分子实体上市数量较 2024 年的48个实现大幅增长、创下纪录，中国已成为全球第二大新分子实体上市国家，国产创新药全球价值获广泛认可。
他指出，我国正迎来创新药工程师红利，科研研发、临床基础设施与研究能力迎来蓬勃发展期。依托完整研发体系与高效落地能力，国内企业可快速跟进前沿发现，率先推进全新分子的 Ⅰ、Ⅱ 期临床并完成 POC 验证，产业创新效率与竞争力显著提升。
当前，全球药企对中国创新药资产高度关注，美国 MNC（跨国制药企业）纷纷来华扫货布局，积极寻找新靶点、开展早期 AI 研发合作。
新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目的，并不意味着赞同其观点或证实其描述。
责任编辑：李思阳
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.